What is the Amino Axiom FDA Tracker?
Amino Axiom's FDA Tracker is a regulatory-status tracker for research compounds. For each compound in the platform's library of 79 research compounds, it records a status label, a context note, and a source reference, so a reader can see how a material is classified without piecing it together from scattered agency notices. It is information only.
Amino Axiom is a free research information platform that gathers a compound library, price comparison, a vendor directory, a compare tool, a glossary, community discussion, and articles in one place. The tracker is a reference page organized by compound. This walkthrough covers what it displays, how a researcher working from compound guides can read it, and where its limits are. Nothing here concerns use of any compound.
Compound guides and regulatory status answer different questions. A guide explains what a molecule is: its sequence, formula, weight, structural class, and the published research around it. A status record explains how an agency or a body of rules classifies the material. A researcher who reads only the first kind of source can come away with a clear picture of the chemistry and no picture at all of the regulatory setting, and the reverse is just as common.
What does the tracker show for each compound?
Each entry is built around a short set of fields. The names and layout may change over time, so the structure below describes the general idea rather than a fixed schema:
- A compound name and common aliases, so the same material is matched even when sources use different labels.
- A status label, which places the compound in a category such as approved for a specific product, studied in clinical trials, listed under a restriction, or without a formal designation.
- A short note on context, which explains in plain language why the label applies and what the label does and does not mean.
- A reference to the source of the information, so a reader can go back to the agency or document the status came from.
The last field is the one that matters most. A status label with no pointer to its source is a claim; a label with a pointer is a lead a researcher can verify. The tracker's value is in collecting the leads in one place and presenting them consistently, not in replacing the underlying documents.
How does a status entry read next to a catalog entry?
Take BPC-157 as a worked example. The Evo Amino catalog lists it with CAS 137525-51-0, molecular formula C62H98N16O22, and a molecular weight of 1419.56 g/mol. Those three figures are identity facts: they describe the molecule and would be the same in any country, under any rulebook.
A status entry is a different type of fact. It is not a property of the molecule at all. It is a property of the molecule's relationship to a particular set of rules, in a particular jurisdiction, as of a particular date. That is why the same compound can carry a status label that changes over time while its CAS number never does. Reading the catalog entry and the tracker entry together separates the two kinds of information cleanly: the catalog says what the material is, the tracker says how it is currently classified.
This pairing is useful when assembling a compound guide of your own notes. A reasonable template has an identity block copied from the catalog, a literature block summarizing published findings in prose, and a status block that records the tracker's label, the date it was checked, and the source it points to. Keeping the three blocks separate prevents a common error, which is letting a regulatory label slip into a sentence that sounds like a statement about the compound's biology.
How do different compounds illustrate the range of statuses?
Semax is a useful second example because its catalog entry looks ordinary while its regulatory context is not the same as that of many other catalog compounds. The Evo Amino catalog lists CAS number 80714-61-0, formula C37H51N9O10S, and molecular weight 813.93 g/mol. Nothing in those figures hints at how the material is classified anywhere. A researcher who wants to know has to look elsewhere, and the tracker is one place to look.
TB-500 makes a third reference point. The catalog lists CAS number 885340-08-9, formula C38H68N10O14, and molecular weight 868.99 g/mol. As with the other two, the identity data is complete and the status data is absent from the catalog by design, because a product catalog is a poor home for information that changes with rule updates.
Reading three entries in a row shows what the tracker is for. The compounds differ in structure and in literature, and they can differ in status label too, even though their catalog entries share the same shape: a CAS number, a formula, a weight, a purity figure, and the same cold, lyophilized storage line. The sameness of the catalog format is exactly why a separate status source is needed. It tells a reader nothing about regulation, so the reader needs another reference to avoid assuming that similar-looking entries are similarly classified.
How should a researcher read a status label?
Read a status label as a dated snapshot tied to one jurisdiction, then check its context note and source reference before drawing any conclusion. A label describes a compound's relationship to a rulebook, never its biology, and it compresses a lot of qualification into a word or two. Four habits make the tracker more reliable as a reading aid.
First, treat the label as a snapshot. Regulatory classifications are revised, and a label that was accurate when a page was written can lag behind a later notice. The tracker's source reference is the way to check whether anything has moved.
Second, read the context note, not only the label. A short label such as "restricted" or "under review" compresses a lot. The note is where the qualifications live: which category of use the status applies to, which jurisdiction it concerns, and what it leaves undecided.
Third, keep jurisdiction in view. A status that applies in one country says little about another. A researcher comparing sources should note which agency each label comes from before drawing any comparison between two compounds.
Fourth, separate status from evidence. A compound can have a restrictive label and a deep literature, or a permissive label and a thin one. The two axes are independent, and a guide that conflates them misleads. Published research findings should be traced to the papers themselves, described in prose, and kept apart from any statement about classification.
How do you read an FDA Tracker entry, step by step?
A researcher building a comparison between two catalog compounds can work through the tracker in a fixed order, as of October 2026 or whatever date the check is made. The order keeps identity facts, literature, and status in separate layers so they can be read against each other. Here is the sequence, step by step:
- Copy the identity data from the two catalog entries and confirm that each formula and molecular weight are consistent with each other.
- Summarize what published structural analyses and in vitro studies describe for each compound, without extending those findings beyond what the papers support.
- Open the FDA Tracker entry for each compound and record its status label, the source it points to, and the date checked.
- Read the three layers against each other and note any place where they seem to disagree, since a mismatch usually means one source is out of date.
- Follow the source reference for any label that matters to the notes, and read the underlying document before relying on the summary.
The tracker saves time at the third step, where the alternative is searching several agency sites for each compound and reconciling their wording by hand. It does not remove the need to read the sources behind a label, and it does not make the label a conclusion about the compound.
What are the limits of a status tracker?
A tracker is a secondary source. It summarizes documents written by others, and a summary can lag, compress, or omit detail. It is also a general-purpose reference, so it cannot address the specifics of any one research program or any one institution's own rules. Where a status question carries real consequences, the agency documents and the institution's compliance office are the authorities, and the tracker is a starting point for finding them.
It is also worth remembering what the tracker does not claim. It does not rate compounds, rank them, or assess their quality, and a status label is not a statement about whether a material is well made. Quality questions belong with analytical data such as chromatograms and mass spectra, and regulatory questions belong with the agencies. Keeping those three categories apart is most of what careful compound-guide reading comes down to. For the quality side, the Evo Amino article on COA batch traceability covers how analytical records tie to a lot, and a side-by-side example of two compounds' literatures is in BPC-157 vs Melanotan 2.
Research use only
Amino Axiom's FDA Tracker and the Evo Amino compound guides discussed here are informational resources. All compounds referenced in this article are supplied strictly for laboratory research purposes and are not intended for human or veterinary use, and nothing in this article is a recommendation about any compound or any activity. For research purposes only.
